ABBV AbbVie Inc.

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

  • National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec 
  • One biotech will receive a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, as well as access to AbbVie's scientific and business executives support and mentorship
  • Applications will be accepted until February 20, 2026.

MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster innovation and support growth in Quebec's life sciences sector.

AbbVie is pleased to collaborate with adMare BioInnovations, an organization dedicated to building strong Canadian life science companies with global impact, to support early-stage biotechnology startup companies with the potential to generate transformational therapies in areas that align with AbbVie's therapeutic areas of focus: immunology, oncology, neuroscience, eye care, and aesthetics.

The award, funded by AbbVie, will provide one early-stage biotech recipient with a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, Quebec. The startup selected will also benefit from AbbVie's scientific and business executives’ expertise and counsel to serve as an accelerator of science.

“This award reflects adMare’s focus on helping to create and scale globally competitive Canadian life science companies,” said Gordon C. McCauley, President and CEO of adMare BioInnovations. We are honoured to partner with AbbVie to provide one of Canada’s next biotech leaders with dedicated turn-key wet lab and office space in our Montreal Innovation Centre so that they can build value by focusing on advancing their technology to achieve scientific milestones and ultimately bring life-changing innovation to patients, faster.”

"We are delighted to bring this exciting biotech award to researchers in Quebec, highlighting AbbVie's commitment to fostering a thriving life sciences ecosystem and tackling patients’ most challenging health issues," said Rami Fayed, Vice President and General Manager of AbbVie Canada. "We look forward to collaborating with adMare BioInnovations and the selected award recipient to help advance meaningful health innovation that will have a remarkable impact on people’s lives."

Applications are being accepted from today through February 20, 2026. For more information on the application requirements and judging criteria, or to submit an application, please visit .

Quebec's vibrant life sciences and health technologies industry contributes $6.5 billion to Quebec’s GDP.1

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

For more information about AbbVie, please visit us at . Follow AbbVie Canada on or find us on .

About adMare BioInnovations

With a strong track record of globally-competitive scientific discovery, Canadian life sciences are primed to lead the world. To make this a reality, adMare BioInnovations uses its scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, develop robust ecosystems, and foster industry-ready talent. It re-invests its returns into the Canadian industry to ensure its long-term sustainability. adMare has helped build 38 companies, of which 27 are still active. These companies have attracted $2.5 billion of risk capital, have a combined value of $5.8 billion, and have created around 1,000 jobs in Canada. Our dynamic Montreal and Vancouver Innovation Centres have been home to 50 life science companies to date, with the 29 current resident companies employing over 400 life sciences professionals. The adMare Academy has trained more than 900 alumni — 87% of whom are employed in the life sciences industry. For more information, please visit . 

Media Inquiries:

Dominique TouchetteBethany Moir
External Communication ManagerSenior Director, Public Affairs
AbbVie CanadaadMare BioInnovations
 




1 BIOQuébec. The Voice of the Industry. Available at: /en/



EN
25/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AbbVie Inc.

AbbVie Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

 PRESS RELEASE

L’Agence des médicaments du Canada émet une recommandation positive po...

L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne SKYRIZI®, un inhibiteur de l’interleukine 23 (IL-23), a fait l’objet de deux recommandations consécutives de l’Agence des médicaments du Canada (AMC) visant son remboursement pour le traitement des maladies inflammatoires de l’intestin, initialement pour la maladie de Crohn et maintenant pour la colite ulcéreuse. Ces recommandations s’appuient sur l...

 PRESS RELEASE

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation...

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie c...

 PRESS RELEASE

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with ...

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec One biotech will receive a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, as well as access to AbbVie's scientific and business executives support and mentorshipApplications will be accepted until February 20, 2026. MONTREAL, Nov...

 PRESS RELEASE

Lancement du Prix AbbVie des innovateurs en biotechnologies au Québec ...

Lancement du Prix AbbVie des innovateurs en biotechnologies au Québec : AbbVie et adMare BioInnovations encouragent l’innovation dans le domaine des sciences de la vie Le lancement d’un concours national, en collaboration avec adMare BioInnovations, illustre l’engagement d’AbbVie à favoriser le dynamisme de l’écosystème des biotechnologies au Québec.L’entreprise biotechnologique lauréate se verra offrir gratuitement pendant un an des espaces de laboratoire et de bureau au Centre d’innovation adMare, ainsi que du matériel et des services partagés, et bénéficiera du soutien et du mentorat de ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch